Skip to main content

Evergraf 0.5 mg | Everolimus | Blueberry pharmaceuticals

EVERGRAF 0.5MG

EVERGRAF 0.5MG belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor).
EVERGRAF 0.5MG is an immunosuppressive macrolide.

USED FOR

Breast cancer 
the patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Rapact. EVERGRAF 0.5MG is used in an advanced stage of breast cancer.

Neuroendocrine tumors 
EVERGRAF 0.5MG involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer.

Renal cell cancer 
patient treating with EVERGRAF 0.5MG after the failure of treatment with Sunitinib or Sorafenib.
EVERGRAF 0.5MG also used in the condition of;
Heart, liver, kidney transplantation
Waldenström macroglobulinemia
Other carcinoid tumors.

MECHANISM OF ACTION

Evergraf is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase.
Evergraf bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR complex 1 (mTORC1) this leads to inhibition of mTOR kinase activity.
Evergraf decreased the effect of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E binding protein (4E-BP1) which are essential for protein synthesis.
mTOR inhibited by Evergraf lead to reduce cell multiplication and angiogenesis.

DOSAGE AND ADMINISTRATION

The recommended dose of the Tablet Evergraf is 10mg should be taken as a single dose in all carcinogenic condition, except organ transplantation.
Organ transplant: 0.75mg orally twice daily.
Brain/intracranial tumor: 4.5mg/m2 orally once a day (for both pediatric and adult dose)
Hepatic impairment: dose reduced to 7.5mg once daily followed by 5mg as a single dose.
Evergrafis in tablet form. It should be administered orally at the same time every day.
Evergrafshould is taken with or without food.
Evergraftablets should not crush or broken.

SIDE EFFECTS

The side effects of EVERGRAF 0.5MG tablets are predicted by the terms of their onset, duration, and severity
Side effects of EVERGRAF 0.5MG are preventable and it is minimized :
Mouth sores, Mucositis, Stomatitis or esophagitis, Infection, Rash, itching or dry skin, Fatigue, Diarrhea, Edema, Stomach pain, Nausea, vomiting, Fever, Weakness or asthenia, Headache.

STORAGE

EVERGRAF 0.5MG should be stored in room temperature
Keep away from moisture, heat, and light

MISSED DOSE

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them.
On the other hand, the missed dose should be avoiding and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:
info@blueberrypharma.com

PHONE:
+91-97890 77748

VISIT US:
Labels:

Comments

Post a Comment

Popular posts from this blog

EVEROLIMUS TABLETS COST IN INDIA

EVEROLIMUS DESCRIPTION  Everolimus  belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor).  Everolimus  is an immunosuppressive macrolide. EVEROLIMUS USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with  Everolimus .  Everolimus  is used in the advanced stage of breast cancer. Neuroendocrine tumors  Everolimus involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer Patient treating with  Everolimus  after the failure of treatment with Sunitinib or Sorafenib.  Everolimus  also used in the condition of Heart, liver, kidney transplantation, Waldenstrom macroglobulinemia, Other carcinoid tumors Brand: Evertor Strength: 10mg Ingredient: Everolimus Company Name: Biocon Tab Count: 10 Tablets MECHANISM OF ACTION Everolimus  is the prohibition o
1 comment
Read more

Nivolumab (Opdivo & Opdyta) Injection Online | Blueberry pharmaceuticals

NIVOLUMAB Nivolumab belongs to a group of cancer drugs known as monoclonal antibodies. Nivolumab is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells. Nivolumab is a prescription drug which is used under the supervision of a doctor INDICATION Nivolumab is indicated for the treatment of patients having Melanoma. Nivolumab is indicated for the treatment of patients having Non-Small Cell Lung Cancer. Nivolumab is indicated for the treatment of patients having Kidney (Renal Cell) Cancer. MECHANISM OF ACTION Nivolumab prohibits the molecule activity called PD-1, and it is a protein which prevents T cells from recognizing and attacking inflamed tissues and cancer cells. PD-1 can deceit the immune system into overlooking melanoma cells as normal cells. DOSAGE AND ADMINISTRATION Nivolumab recommended dosage for unresectable or metastatic melanoma : As a single
Post a Comment
Read more

Evertor 5 mg | Everolimus | Blueberry pharmaceuticals

EVERTOR 5MG Evertor 5mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Evertor 5mg is an immunosuppressive macrolide. EVERTOR USED FOR Breast cancer  The patient who failed to respond to the tablet letrozole or anastrozole therapy, would be treated with Evertor. Evertor 5mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Evertor 5mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  patient treating with Evertor 5mg after the failure of treatment with Sunitinib or Sorafenib. Evertor also used in the condition of: Heart, liver, kidney transplantation Waldenstrom macroglobulinemia Other carcinoid tumors MECHANISM OF ACTION Evertor is prohibitor of mammalian target of rapamycin (mTOR), a serine threonine kinase. Evertor bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR comple
Post a Comment
Read more